Regenerx Biopharm In Insiders

RGRXDelisted Stock  USD 0.0009  0.0001  12.50%   
Regenerx Biopharm employs about 3 people. The company is managed by 8 executives with a total tenure of roughly 139 years, averaging almost 17.0 years of service per executive, having 0.38 employees per reported executive. Break down of Regenerx Biopharm's management performance can provide insight into the company performance.
J Finkelstein  CEO
CEO and President and Director
Allan Goldstein  Chairman
Founder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory Board
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Regenerx Biopharm Management Team Effectiveness

The company has return on total asset (ROA) of (0.8397) % which means that it has lost $0.8397 on every $100 spent on assets. This is way below average. Regenerx Biopharm's management efficiency ratios could be used to measure how well Regenerx Biopharm manages its routine affairs as well as how well it operates its assets and liabilities.

Regenerx Biopharm Workforce Comparison

Regenerx Biopharm In is rated third in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 374. Regenerx Biopharm maintains roughly 3.0 in number of employees contributing less than 1% to equities under Health Care industry.

Regenerx Biopharm Notable Stakeholders

A Regenerx Biopharm stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Regenerx Biopharm often face trade-offs trying to please all of them. Regenerx Biopharm's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Regenerx Biopharm's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
J FinkelsteinCEO and President and DirectorProfile
Allan GoldsteinFounder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory BoardProfile
Don ElseyIndependent DirectorProfile
Alessandro NosedaDirectorProfile
Joseph McNayIndependent DirectorProfile
Raymond ElseyIndependent DirectorProfile
Mauro BoveIndependent DirectorProfile
Nabila TurjmanEx AffairsProfile

About Regenerx Biopharm Management Performance

The success or failure of an entity such as Regenerx Biopharm often depends on how effective the management is. Regenerx Biopharm management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Regenerx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Regenerx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland. REGENERX BIOPHARMACEUTICA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
The data published in Regenerx Biopharm's official financial statements usually reflect Regenerx Biopharm's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Regenerx Biopharm. For example, before you start analyzing numbers published by Regenerx accountants, it's critical to develop an understanding of what Regenerx Biopharm's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Regenerx Biopharm's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Regenerx Biopharm's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Regenerx Biopharm's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Regenerx Biopharm In. Please utilize our Beneish M Score to check the likelihood of Regenerx Biopharm's management manipulating its earnings.

Regenerx Biopharm Workforce Analysis

Traditionally, organizations such as Regenerx Biopharm use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Regenerx Biopharm within its industry.

Regenerx Biopharm Manpower Efficiency

Return on Regenerx Biopharm Manpower

Revenue Per Employee25.6K
Revenue Per Executive9.6K
Net Loss Per Employee532.6K
Net Loss Per Executive199.7K
Working Capital Per Employee268.7K
Working Capital Per Executive100.8K
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Consideration for investing in Regenerx OTC Stock

If you are still planning to invest in Regenerx Biopharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regenerx Biopharm's history and understand the potential risks before investing.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Commodity Directory
Find actively traded commodities issued by global exchanges
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope